$16.00+0.10 (+0.63%)
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
Polyrizon Ltd. in the Healthcare sector is trading at $16.00. The stock is currently near its 52-week low of $2.88, remaining 65.5% above its 200-day moving average. Technical signals show overbought RSI of 76 and bullish MACD crossover, explaining why PLRZ maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a r...
Polyrizon shares have skyrocketed this week on breakthrough preclinical data for its naloxone hydrogen. But PLRZ stock remains a risky proposition heading into 2026.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
HIVE Digital Technologies Ltd. 15,939,276 3.3797
Smart Digital Group (SDM) said late Thursday that it priced its initial public offering of 1.5 milli